Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Biophytis S.A. (BPTS) shares surged 53.9% after signing a partnership with SEQENS to produce Sarconeos (BIO101) active compound. Aridis Pharmaceuticals, Inc. (ARDS) shares gained 41.8% after EMA announced positive feedback on the company's proposed Phase 3 study AR-301. Karyopharm Therapeutics Inc. (KPTI) rose 26.1% after receiving FDA Fast Track Designation for Selinexor for Myelofibrosis. 9 Meters Biopharma, Inc. (NMTR) fell 59% and Masimo Corporation (MASI) fell 27.3% after reporting weak preliminary revenue results for Q2.
July 18, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aridis Pharmaceuticals shares gained after EMA announced positive feedback on the company's proposed Phase 3 study AR-301.
The positive feedback from EMA on the company's proposed Phase 3 study AR-301 is a positive development for Aridis Pharmaceuticals, which is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Biophytis shares surged after signing a partnership with SEQENS to produce Sarconeos (BIO101) active compound.
The partnership with SEQENS to produce Sarconeos (BIO101) active compound is a positive development for Biophytis, which is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Karyopharm Therapeutics shares rose after receiving FDA Fast Track Designation for Selinexor for Myelofibrosis.
The FDA Fast Track Designation for Selinexor for Myelofibrosis is a positive development for Karyopharm Therapeutics, which is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Masimo Corporation shares fell 27.3% after the company reported weak preliminary revenue results for the second quarter.
The weak preliminary revenue results for the second quarter is a negative development for Masimo Corporation, which is likely to have a negative impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
9 Meters Biopharma shares fell 59%.
There is no specific news mentioned in the article that could have caused the fall in 9 Meters Biopharma's stock price. However, the significant drop indicates a negative sentiment among investors, which is likely to have a negative impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100